Measured Success at Renue By Science
10 years moving the science forward as the global leader in NAD+ product development. We build every formula around cellular energy and healthy aging using delivery methods that make NAD+ work better.
RENUE BY SCIENCE PROMISE.
NAD+ Declines With Age.Most Supplements Just Mask It.
Your cells run on a molecule called NAD+. The more you have, the better they perform. The less you have, the harder everything gets.By middle age, levels can fall by half, and your energy, recovery, and resilience fall with them.Most supplements just mask the decline. We work where the decline actually starts.We target the pathway. Not just the feeling.
Meet Our Team of Experts
“At the age of 63, I feel like I have the same strength and endurance from my 30s.”
Bryan Nettles, Founder and CEO of Renue By Science, has a lifelong focus on nutrition, exercise, and longevity science. His personal health journey - recovering from prostate cancer - deepened his commitment to research and healthy aging. Driven to educate and empower others, he founded the company to make science-backed longevity solutions more accessible, helping people live longer, stronger lives at any stage.
Bryan Nettles
Founder & CEO
Liposomal Delivery Means Greater Bioavailability.
Liposomal delivery wraps sensitive ingredients like NMN and NR in phospholipids, the same fats that make up cell membranes, so they're protected during digestion and first-pass liver processing.
The result: more of the active ingredients reach your cells, so a smaller dose can deliver significantly more support than standard formulas.
Our Contributions & Constant Objectives
Liposomal delivery for NAD+ precursors: NMN and NR.
The challenge with NAD+ precursors.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) face unique absorption challenges that make them ideal candidates for liposomal delivery. Research has identified that NMN is absorbed through the small intestine, including transporters like SLC12A8, with the CD73 enzyme facilitating uptake, but this process is pH-dependent and can be compromised by stomach acid.²³ Additionally, both compounds are rapidly metabolized: NMN can be broken down to nicotinamide by CD38 and other enzymes before reaching target tissues.²⁴
Studies show that while oral NMN does raise NAD+ levels, the conversion efficiency varies significantly between individuals, likely due to differences in digestive conditions and enzyme activity.²⁵ NR faces similar challenges, with intestinal and hepatic metabolism converting much of it to nicotinamide before it can raise NAD+ in target tissues.²⁶